Previous 10 | Next 10 |
MENLO PARK, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Thomas Leung as chief financial officer. Mr. Leung w...
Adverum ( ADVM ) announced that one of its gene therapy products , known as ADVM-022, was placed on a clinical hold. It was just an issue the FDA had with CMC data. This, in essence, deals with the FDA needing additional information for manufacturing and processing of the gene therapy ADVM-02...
MENLO PARK, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new preclinical data at upcoming conferences, including t...
Adverum Biotechnologies ( ADVM -7.2% ) is down on below-average volume in reaction to its announcement that the FDA has placed a clinical hold on its Phase 1 study, OPTIC , evaluating gene therapy candidate ADVM-022 in patients with wet age-related macular degeneration (wet AMD) citing ...
- Clinical Hold until Additional CMC Information is Reviewed by FDA - - Independent DMC Review of Safety Data from First Cohort of Six Patients with No SAEs or DLTs - - Adverum Plans to Present 24-Week Data from First Cohort of Patients at Scientific Meeting in 2H19 - MENLO P...
MENLO PARK, Cali., April 01, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Aaron Osborne, MBBS MRCOphth as chief medical officer, effe...
Gainers: Seelos Therapeutics (NASDAQ: SEEL ) +40% . Hibbett Sports (NASDAQ: HIBB ) +23% . Bio-Path Holdings (NASDAQ: BPTH ) +18% . Immutep (NASDAQ: IMMP ) +17% . CounterPath (NASDAQ: CPAH ) +12% . Destination Maternity (NASDAQ: DEST ) +11% . Netshoes (NYSE: NETS ) +11% . AC Im...
MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the Company’s participation in several upcoming conferences: Event:...
The following slide deck was published by Adverum Biotechnologies, Inc. in conjunction with this Read more ...
Adverum Biotechnologies (NASDAQ: ADVM ): Q4 GAAP EPS of -$0.25. More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash...
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 20...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...